US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Elicio Therapeutics

5.47

-0.2400-4.20%

Volume:27.23K

Turnover:153.82K

Market Cap:87.19M

PE:-1.29

High:5.75

Open:5.75

Low:5.46

Close:5.71

Loading ...

Overview Company News Filings

Elicio Therapeutics reports Q1 EPS (87c), consensus (83c)

BRIEF-Elicio Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Updates

Elicio Therapeutics Q1 EPS $(0.87) Misses $(0.83) Estimate

Elicio Therapeutics Reports Q1 2025 Financial Results: Net Loss Decreases to $11.2M, EPS Improves to $(0.87) from $(1.15)

Elicio Therapeutics Q1 Operating Expenses USD 10.736 Million

THOMSON REUTERS

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

THOMSON REUTERS

Elicio Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview

Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher

Press Release: Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?

Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know

Elicio Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple

BUZZ-Elicio signals delay in mid-stage cancer vaccine study; shares slump

Elicio Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Elicio Therapeutics FY 2024 GAAP EPS $(4.25) Misses $(3.56) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $17.6M. Including $10M In Gross Proceeds From January 2025 Registered Direct Offering, The Company Expects Cash Runway Into Q4 2025

Press Release: Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview

Elicio Therapeutics Names Preetam Shah CFO

MT Newswires Live

Elicio Therapeutics Hires CFO From Cidara Therapeutics

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ELTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELTX\",,,,,undefined,":{"symbol":"ELTX","market":"US","secType":"STK","nameCN":"Elicio Therapeutics","latestPrice":5.47,"timestamp":1747241584749,"preClose":5.71,"halted":0,"volume":27227,"delay":0,"floatShares":10268391,"shares":15939069,"eps":-4.25289,"marketStatus":"Trading","change":-0.24,"latestTime":"05-14 13:00:42 EDT","open":5.75,"high":5.75,"low":5.455,"amount":153822.693826,"amplitude":0.051664,"askPrice":5.58,"askSize":200,"bidPrice":5.48,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.25289,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1747252800000},"marketStatusCode":2,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":5.71,"postHourTrading":{"tag":"盘后","latestPrice":5.71,"preClose":5.71,"latestTime":"16:37 EDT","volume":20,"amount":114.2,"timestamp":1747168624893},"volumeRatio":1.794328,"impliedVol":0.5908,"impliedVolPercentile":0.7},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELTX\",,,,,undefined,":{"symbol":"ELTX","floatShares":10268391,"roa":"-101.64%","roe":"-170157.38%","lyrEps":-4.25289,"volumeRatio":1.794328,"shares":15939069,"dividePrice":0,"high":5.75,"amplitude":0.051664,"preClose":5.71,"low":5.455,"week52Low":3.3419,"pbRate":"-7.71","week52High":11.45,"institutionHeld":0,"latestPrice":5.47,"committee":-0.333333,"eps":-4.25289,"divideRate":0,"volume":27227,"delay":0,"ttmEps":-4.25289,"open":5.75,"prevYearClose":5.1,"prevWeekClose":5.49,"prevMonthClose":4.92,"prevQuarterClose":6.16,"fiveDayClose":4.96,"twentyDayClose":4.98,"sixtyDayClose":8.05},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535080136","title":"Elicio Therapeutics reports Q1 EPS (87c), consensus (83c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535080136","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535080136?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:55","pubTimestamp":1747169738,"startTime":"0","endTime":"0","summary":"“In the first quarter, we made continued progress toward our upcoming Phase 2 AMPLIFY-7P event-driven interim analysis, expected next quarter-a key...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-reports-q1-eps-87c-consensus-83c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-reports-q1-eps-87c-consensus-83c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELTX"],"gpt_icon":0},{"id":"2535087185","title":"BRIEF-Elicio Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535087185","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535087185?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:41","pubTimestamp":1747168880,"startTime":"0","endTime":"0","summary":"BRIEF-Elicio Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate UpdatesMay 13 (Reuters) - Elicio Therapeutics Inc ELTX.O:ELICIO THERAPEUTICS REPORTS FIRST QUARTER 2025 FI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA8JDTNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2535824380","title":"Elicio Therapeutics Q1 EPS $(0.87) Misses $(0.83) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535824380","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535824380?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:28","pubTimestamp":1747168125,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.83) by 4.82 percent. This is a 24.35 percent increase over losses of $(1.15) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45391258/elicio-therapeutics-q1-eps-0-87-misses-0-83-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0},{"id":"2535084879","title":"Elicio Therapeutics Reports Q1 2025 Financial Results: Net Loss Decreases to $11.2M, EPS Improves to $(0.87) from $(1.15)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535084879","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535084879?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:06","pubTimestamp":1747166801,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDLbhWvnH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","ELTX"],"gpt_icon":0},{"id":"2535081792","title":"Elicio Therapeutics Q1 Operating Expenses USD 10.736 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535081792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535081792?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nPLX693B95:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2535081204","title":"Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535081204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535081204?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA8JDTNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2534834034","title":"Elicio Therapeutics Inc  expected to post a loss of 83 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2534834034","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534834034?lang=en_us&edition=fundamental","pubTime":"2025-05-09 19:54","pubTimestamp":1746791659,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc  expected to post a loss of83cents a share - Earnings Preview Elicio Therapeutics Inc ELTX.OQ ELTX.O is expected to show no change in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH1F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0},{"id":"2532007319","title":"Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher","url":"https://stock-news.laohu8.com/highlight/detail?id=2532007319","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532007319?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:55","pubTimestamp":1746107702,"startTime":"0","endTime":"0","summary":"Shares of Elicio Therapeutics  have been struggling lately and have lost 5.8% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this company enhances its prospects of a trend reversal.Understanding Hammer Chart and the Technique to Trade It. If this is not enough, you should note that ELTX currently has a Zacks Rank #2 , which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-elicio-therapeutics-eltx-135502452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CHH","BK4142","ELTX","BK4007"],"gpt_icon":0},{"id":"2528277617","title":"Press Release: Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2528277617","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528277617?lang=en_us&edition=fundamental","pubTime":"2025-04-17 04:05","pubTimestamp":1744833900,"startTime":"0","endTime":"0","summary":"BOSTON, April 16, 2025  -- Elicio Therapeutics, Inc. , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2025, Elicio granted inducement awards to Elicio's newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two additional new employees, as an inducement material to Dr. Shah and such employees entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635, which grants were approved by the compensation committee of Elicio's board of directors in accordance with the Elicio 2024 Inducement Incentive Award Plan.The grant to Dr. Shah provides for the issuance of 191,624 stock options. Additionally, the grants to the two employees provide for the issuance of an aggregate of 21,000 stock options. Each grant provides for the purchase of shares of Elicio common stock at a price of $4.98 per share, the closing price per share of Elicio common stock as reported","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","ELTX","BK4139","BK4007"],"gpt_icon":1},{"id":"2524848407","title":"Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524848407","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524848407?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:40","pubTimestamp":1743774011,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Elicio Therapeutics  been one of those stocks this year?By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Elicio Therapeutics is a member of the Medical sector. This group includes 1003 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Elicio Therapeutics is currently sporting a Zacks Rank of #2 .Inventiva S.A. Sponsored ADR  is another Medical sto","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elicio-therapeutics-inc-eltx-stock-134011044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IVA","BK4139","BK4007","ELTX"],"gpt_icon":0},{"id":"2524914832","title":"Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2524914832","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524914832?lang=en_us&edition=fundamental","pubTime":"2025-04-04 00:00","pubTimestamp":1743696009,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 . This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for Elicio Therapeutics is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elicio-therapeutics-eltx-upgraded-buy-160009591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ELTX"],"gpt_icon":0},{"id":"2524464075","title":"Elicio Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524464075","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524464075?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:50","pubTimestamp":1743594600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ELTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 07:50 ET (11:50 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0},{"id":"2524047975","title":"BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple","url":"https://stock-news.laohu8.com/highlight/detail?id=2524047975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524047975?lang=en_us&edition=fundamental","pubTime":"2025-04-01 02:29","pubTimestamp":1743445744,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, AppleMarch 31 (Reuters) - The S&P 500 and the Nasdaq declined on Monday, with technology stocks among the largest fallers, as inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL3N3QE16T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","LYV","FBK","COOP","BLUE","IDYA","FLG","GATE","TSHA","LPLA","BK4532","LU0820561818.USD","ENZ","LITB","BK4539","SSBK","SG9999014567.USD","TSYW.SI","HMST","ALNY","BK4017","GSK.UK","LU0061475181.USD","SLDB","LU1674673428.USD","ALSN","NOVA","IIPR","PINS","AIG","GT","LU2552382215.SGD","LU1674673691.USD","SRPT","VBTX","GLPI","SG9999015358.SGD","LU0316494557.USD","PG","PL","RKT","NEM","EBS","LU1145028129.USD","NVAX"],"gpt_icon":1},{"id":"2524978939","title":"BUZZ-Elicio signals delay in mid-stage cancer vaccine study; shares slump","url":"https://stock-news.laohu8.com/highlight/detail?id=2524978939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524978939?lang=en_us&edition=fundamental","pubTime":"2025-04-01 01:25","pubTimestamp":1743441957,"startTime":"0","endTime":"0","summary":"BUZZ-Elicio signals delay in mid-stage cancer vaccine study; shares slump** Biotech firm Elicio Therapeutics' ELTX.O shares fall 14% to an over 2-month low of $6.71  ** ELTX now expects mid-stage study data of its lead experimental vaccine, ELI-002, in Q3 2025 vs. previous expectation of H1 2025** Co is testing vaccine against certain types of solid tumors that are caused by mutations in the KRAS gene, which are common in pancreatic, colorectal, and non-small cell lung cancers** ELTX's net loss also widens in 2024 compared with 2023** As of last close, ELTX has risen 2.5% in the past 12 months","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL3N3QE13X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELTX","BK4007"],"gpt_icon":0},{"id":"2523094221","title":"Elicio Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2523094221","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523094221?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:31","pubTimestamp":1743427876,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryElicio Therapeutics Inc ELTX.OQ reported a quarterly adjusted loss of $1.02 per share for the quarter ended ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL5N3QE0Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0},{"id":"2523103029","title":"Elicio Therapeutics FY 2024 GAAP EPS $(4.25) Misses $(3.56) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $17.6M. Including $10M In Gross Proceeds From January 2025 Registered Direct Offering, The Company Expects Cash Runway Into Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2523103029","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523103029?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:17","pubTimestamp":1743419828,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(4.25) per share which missed the analyst consensus estimate of $(3.56) by 19.38 percent. This is a 38.94 percent increase over losses of $(6.96) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44558596/elicio-therapeutics-fy-2024-gaap-eps-4-25-misses-3-56-estimate-as-of-december-31-2024-cash-and-cash","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0},{"id":"2523912207","title":"Press Release: Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2523912207","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523912207?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival  event-driven interim analysis expected in Q3 2025. Aligned with U.S. Food and Drug Administration  on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis. Strengthened cash position to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis. BOSTON, March 31, 2025  -- Elicio Therapeutics, Inc. , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2024 and provided recent corporate and clinical updates.-- In March 2025, Elicio appointed Preetam Shah, Ph.D., MBA, as Chief. -- In January 2025, Elicio strengthened its cash position with a $10.0. a registrational strategy for ELI-002 in post-resection (adjuvant. Elicio aligned with the FDA on key elements of a planned Phase 3 study","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ELTX"],"gpt_icon":0},{"id":"2522078161","title":"Elicio Therapeutics Inc  expected to post a loss of 87 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522078161","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522078161?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:32","pubTimestamp":1742905973,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc  expected to post a loss of87cents a share - Earnings Preview Elicio Therapeutics Inc ELTX.OQ ELTX.O is expected to show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL5N3Q80Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0},{"id":"2521742428","title":"Elicio Therapeutics Names Preetam Shah CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2521742428","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521742428?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:57","pubTimestamp":1742817478,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (ELTX) said Monday that it has named Preetam Shah as its chief financial officer and chief strategy officer, starting immediately.Shah previously was CFO and chief business officer of biotech firm Cidara Therapeutics (CDTX).","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ELTX","BK4139","CDTX","BK4007"],"gpt_icon":0},{"id":"2521974283","title":"Elicio Therapeutics Hires CFO From Cidara Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2521974283","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521974283?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:46","pubTimestamp":1742816760,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics has hired the former chief financial officer of Cidara Therapeutics to lead its strategy and finances.The Boston-based Elicio said Monday that Preetam Shah has been appointed chief strategy and financial officer.Shah will also serve as the biotechnology company's principal financial officer and principal accounting officer.He most recently served as the chief financial officer and chief business officer of fellow biotech Cidara. Before that, Shah was the CFO for Brainstorm Cell Therapeutics and has held roles at Barclays Capital and Canaccord Genuity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELTX","CDTX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELTX\",params:#limit:5,,,undefined,":[{"date":"2025-05-13","symbol":"ELTX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1747166400000,"name":null,"time":"Post Market","dateTimestamp":1747108800000,"actualEps":null},{"market":"US","date":"2025-03-31","symbol":"ELTX","fiscalQuarterEnding":"2024/12","expectedEps":-0.94,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.02},{"market":"US","date":"2024-11-13","symbol":"ELTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.81,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.39},{"market":"US","date":"2024-08-13","symbol":"ELTX","fiscalQuarterEnding":"2024/06","expectedEps":-0.96,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2024-05-15","symbol":"ELTX","fiscalQuarterEnding":"2024/03","expectedEps":-1.09,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ELTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ELTX","date":"2025-05-13","current":-1.695319,"percent":0.477169,"low":-9.235249,"twenty":-2.588663,"median":-1.632359,"eighty":-1.235702,"high":-0.963611,"avg":-1.949347,"sd":1.017108,"marketCap":87983660},"quantilePoints":[{"date":"2023-06-09","current":-9.235249,"twenty":-9.235249,"median":-9.19865,"eighty":-8.861936,"marketCap":260505032},{"date":"2023-06-16","current":-4.797096,"twenty":-9.19133,"median":-5.471097,"eighty":-5.286091,"marketCap":135315000},{"date":"2023-06-23","current":-3.669177,"twenty":-9.011993,"median":-5.35246,"eighty":-4.343178,"marketCap":103499000},{"date":"2023-06-30","current":-3.232452,"twenty":-8.711878,"median":-5.281964,"eighty":-3.931212,"marketCap":91180000},{"date":"2023-07-07","current":-3.782657,"twenty":-7.82363,"median":-4.797096,"eighty":-3.594899,"marketCap":106700000},{"date":"2023-07-14","current":-3.799851,"twenty":-5.457342,"median":-4.009616,"eighty":-3.669177,"marketCap":107185000},{"date":"2023-07-21","current":-3.868626,"twenty":-5.416077,"median":-3.868626,"eighty":-3.616907,"marketCap":109125000},{"date":"2023-07-28","current":-3.026831,"twenty":-5.342487,"median":-3.782657,"eighty":-3.314983,"marketCap":85379914},{"date":"2023-08-04","current":-2.958445,"twenty":-5.286091,"median":-3.758585,"eighty":-2.99472,"marketCap":83450898},{"date":"2023-08-11","current":-2.973312,"twenty":-5.075638,"median":-3.643386,"eighty":-2.969744,"marketCap":83870250},{"date":"2023-08-18","current":-2.842099,"twenty":-4.570137,"median":-3.57633,"eighty":-2.953093,"marketCap":83656289},{"date":"2023-08-25","current":-2.726636,"twenty":-4.18018,"median":-3.222136,"eighty":-2.868421,"marketCap":79553028},{"date":"2023-09-01","current":-2.370739,"twenty":-4.067388,"median":-3.000071,"eighty":-2.849368,"marketCap":69169264},{"date":"2023-09-07","current":-2.433882,"twenty":-3.951844,"median":-2.973312,"eighty":-2.844375,"marketCap":71011545},{"date":"2023-09-15","current":-2.413791,"twenty":-3.886508,"median":-2.973312,"eighty":-2.761879,"marketCap":70425365},{"date":"2023-09-22","current":-2.293245,"twenty":-3.841116,"median":-2.967365,"eighty":-2.647421,"marketCap":66908283},{"date":"2023-09-29","current":-2.413791,"twenty":-3.792973,"median":-2.953985,"eighty":-2.537207,"marketCap":70425365},{"date":"2023-10-04","current":-2.276024,"twenty":-3.782657,"median":-2.940605,"eighty":-2.474064,"marketCap":66405843},{"date":"2023-10-10","current":-2.098075,"twenty":-3.781281,"median":-2.875192,"eighty":-2.428715,"marketCap":61213961},{"date":"2023-10-19","current":-2.009101,"twenty":-3.779218,"median":-2.868708,"eighty":-2.413791,"marketCap":58618021},{"date":"2023-10-27","current":-1.922996,"twenty":-3.775091,"median":-2.867273,"eighty":-2.413791,"marketCap":56105820},{"date":"2023-11-03","current":-1.871334,"twenty":-3.740703,"median":-2.849368,"eighty":-2.290949,"marketCap":54598499},{"date":"2023-11-10","current":-1.690515,"twenty":-3.669177,"median":-2.844944,"eighty":-2.243878,"marketCap":49322877},{"date":"2023-11-17","current":-1.533738,"twenty":-3.658861,"median":-2.768921,"eighty":-2.084298,"marketCap":50453368},{"date":"2023-11-24","current":-1.527374,"twenty":-3.617595,"median":-2.739552,"eighty":-1.974659,"marketCap":50244018},{"date":"2023-12-01","current":-1.565558,"twenty":-3.614157,"median":-2.617571,"eighty":-1.90147,"marketCap":51500118},{"date":"2023-12-08","current":-1.48919,"twenty":-3.583895,"median":-2.583129,"eighty":-1.87076,"marketCap":48987917},{"date":"2023-12-15","current":-1.540102,"twenty":-3.452534,"median":-2.531467,"eighty":-1.708711,"marketCap":50662718},{"date":"2023-12-22","current":-1.476462,"twenty":-3.314983,"median":-2.474064,"eighty":-1.60527,"marketCap":48569217},{"date":"2023-12-29","current":-2.102685,"twenty":-3.232452,"median":-2.429577,"eighty":-1.641927,"marketCap":69169264},{"date":"2024-01-05","current":-2.03949,"twenty":-3.220072,"median":-2.413791,"eighty":-1.611379,"marketCap":67090423},{"date":"2024-01-12","current":-1.576818,"twenty":-3.100826,"median":-2.392265,"eighty":-1.585578,"marketCap":51870515},{"date":"2024-01-19","current":-1.427896,"twenty":-3.005423,"median":-2.30616,"eighty":-1.564031,"marketCap":46971633},{"date":"2024-01-26","current":-1.124213,"twenty":-2.973312,"median":-2.283466,"eighty":-1.540772,"marketCap":36981756},{"date":"2024-02-02","current":-1.314015,"twenty":-2.973312,"median":-2.260238,"eighty":-1.528392,"marketCap":43225429},{"date":"2024-02-09","current":-1.226414,"twenty":-2.973312,"median":-2.227231,"eighty":-1.508027,"marketCap":40343734},{"date":"2024-02-16","current":-1.220574,"twenty":-2.970933,"median":-2.10038,"eighty":-1.496317,"marketCap":40151621},{"date":"2024-02-23","current":-1.170933,"twenty":-2.967365,"median":-2.077039,"eighty":-1.484607,"marketCap":38518660},{"date":"2024-03-01","current":-1.185534,"twenty":-2.965581,"median":-2.037802,"eighty":-1.427936,"marketCap":38998943},{"date":"2024-03-08","current":-1.305255,"twenty":-2.958445,"median":-1.951697,"eighty":-1.350807,"marketCap":42937259},{"date":"2024-03-15","current":-1.530098,"twenty":-2.956661,"median":-1.917256,"eighty":-1.360152,"marketCap":50333611},{"date":"2024-03-22","current":-1.927222,"twenty":-2.947741,"median":-1.909363,"eighty":-1.380707,"marketCap":63397296},{"date":"2024-03-28","current":-2.178345,"twenty":-2.940605,"median":-1.925109,"eighty":-1.425549,"marketCap":71658156},{"date":"2024-04-05","current":-2.18389,"twenty":-2.875192,"median":-1.928736,"eighty":-1.427896,"marketCap":76862025},{"date":"2024-04-12","current":-2.872164,"twenty":-2.872164,"median":-2.000282,"eighty":-1.428095,"marketCap":101085828},{"date":"2024-04-19","current":-2.390082,"twenty":-2.870144,"median":-2.037802,"eighty":-1.436656,"marketCap":84118945},{"date":"2024-04-26","current":-2.64274,"twenty":-2.867273,"median":-2.070475,"eighty":-1.460017,"marketCap":93011227},{"date":"2024-05-03","current":-2.613699,"twenty":-2.860548,"median":-2.080854,"eighty":-1.476462,"marketCap":91989126},{"date":"2024-05-10","current":-2.758904,"twenty":-2.852923,"median":-2.121507,"eighty":-1.483377,"marketCap":97099633},{"date":"2024-05-17","current":-2.458726,"twenty":-2.860548,"median":-2.154849,"eighty":-1.484098,"marketCap":95873111},{"date":"2024-05-24","current":-2.3198,"twenty":-2.852923,"median":-2.20556,"eighty":-1.486644,"marketCap":90455973},{"date":"2024-05-31","current":-1.968554,"twenty":-2.850079,"median":-2.181118,"eighty":-1.488681,"marketCap":76759815},{"date":"2024-06-07","current":-2.125179,"twenty":-2.849368,"median":-2.152608,"eighty":-1.489212,"marketCap":82867106},{"date":"2024-06-14","current":-2.233016,"twenty":-2.846714,"median":-2.152608,"eighty":-1.492255,"marketCap":87071996},{"date":"2024-06-21","current":-1.741174,"twenty":-2.844944,"median":-2.140329,"eighty":-1.496317,"marketCap":67893594},{"date":"2024-06-28","current":-1.812189,"twenty":-2.844944,"median":-2.140329,"eighty":-1.498354,"marketCap":70662668},{"date":"2024-07-05","current":-0.967903,"twenty":-2.843237,"median":-2.110101,"eighty":-1.488172,"marketCap":37741454},{"date":"2024-07-12","current":-1.249432,"twenty":-2.834001,"median":-2.100781,"eighty":-1.469884,"marketCap":48719089},{"date":"2024-07-15","current":-1.260464,"twenty":-2.831302,"median":-2.098877,"eighty":-1.455345,"marketCap":49149280},{"date":"2024-08-02","current":-1.401267,"twenty":-2.828603,"median":-2.098877,"eighty":-1.436656,"marketCap":54639616},{"date":"2024-08-09","current":-1.290931,"twenty":-2.802466,"median":-2.080854,"eighty":-1.401267,"marketCap":50337284},{"date":"2024-08-16","current":-1.201045,"twenty":-2.796658,"median":-2.072003,"eighty":-1.349055,"marketCap":46438413},{"date":"2024-08-23","current":-1.241178,"twenty":-2.769689,"median":-2.062918,"eighty":-1.296495,"marketCap":47990130},{"date":"2024-08-30","current":-1.113164,"twenty":-2.768153,"median":-2.038646,"eighty":-1.281895,"marketCap":43040476},{"date":"2024-09-06","current":-1.110381,"twenty":-2.760754,"median":-2.011962,"eighty":-1.261256,"marketCap":42932874},{"date":"2024-09-13","current":-1.132616,"twenty":-2.753755,"median":-1.991463,"eighty":-1.24953,"marketCap":43792608},{"date":"2024-09-20","current":-1.430415,"twenty":-2.736707,"median":-1.971607,"eighty":-1.23844,"marketCap":55307011},{"date":"2024-09-27","current":-1.355277,"twenty":-2.727862,"median":-1.927222,"eighty":-1.247781,"marketCap":52401779},{"date":"2024-10-04","current":-1.35806,"twenty":-2.717602,"median":-1.920126,"eighty":-1.24953,"marketCap":52509380},{"date":"2024-10-11","current":-1.333014,"twenty":-2.703726,"median":-1.89225,"eighty":-1.251663,"marketCap":51540970},{"date":"2024-10-18","current":-1.327448,"twenty":-2.69392,"median":-1.871334,"eighty":-1.251663,"marketCap":51325767},{"date":"2024-10-25","current":-1.330231,"twenty":-2.68748,"median":-1.868821,"eighty":-1.256738,"marketCap":51433368},{"date":"2024-10-31","current":-1.15769,"twenty":-2.682816,"median":-1.860061,"eighty":-1.249543,"marketCap":44762095},{"date":"2024-11-08","current":-1.282921,"twenty":-2.678751,"median":-1.809791,"eighty":-1.251136,"marketCap":49604148},{"date":"2024-11-15","current":-1.251898,"twenty":-2.674104,"median":-1.720841,"eighty":-1.252073,"marketCap":58642648},{"date":"2024-11-22","current":-1.176095,"twenty":-2.654356,"median":-1.667384,"eighty":-1.249488,"marketCap":55091809},{"date":"2024-11-29","current":-1.171024,"twenty":-2.64274,"median":-1.629813,"eighty":-1.227353,"marketCap":54854273},{"date":"2024-12-06","current":-1.106606,"twenty":-2.639384,"median":-1.600178,"eighty":-1.22448,"marketCap":51836749},{"date":"2024-12-13","current":-1.148018,"twenty":-2.631897,"median":-1.571188,"eighty":-1.222594,"marketCap":53776586},{"date":"2024-12-20","current":-1.167573,"twenty":-2.62396,"median":-1.563013,"eighty":-1.217317,"marketCap":54692620},{"date":"2024-12-27","current":-1.166423,"twenty":-2.616797,"median":-1.547739,"eighty":-1.213926,"marketCap":54638735},{"date":"2025-01-03","current":-1.182527,"twenty":-2.613699,"median":-1.540102,"eighty":-1.211814,"marketCap":55393116},{"date":"2025-01-10","current":-1.304461,"twenty":-2.611376,"median":-1.530098,"eighty":-1.211814,"marketCap":61104858},{"date":"2025-01-17","current":-1.48161,"twenty":-2.609328,"median":-1.528647,"eighty":-1.213041,"marketCap":69403049},{"date":"2025-01-24","current":-1.656458,"twenty":-2.608318,"median":-1.528647,"eighty":-1.213574,"marketCap":77593471},{"date":"2025-01-31","current":-2.167199,"twenty":-2.60789,"median":-1.530098,"eighty":-1.21433,"marketCap":101518124},{"date":"2025-02-07","current":-2.162598,"twenty":-2.593884,"median":-1.54094,"eighty":-1.214734,"marketCap":101302587},{"date":"2025-02-14","current":-1.769189,"twenty":-2.583696,"median":-1.557921,"eighty":-1.214981,"marketCap":82874137},{"date":"2025-02-21","current":-1.863515,"twenty":-2.577932,"median":-1.565558,"eighty":-1.217317,"marketCap":87292655},{"date":"2025-02-28","current":-1.902626,"twenty":-2.570137,"median":-1.584118,"eighty":-1.220574,"marketCap":89124723},{"date":"2025-03-07","current":-1.833607,"twenty":-2.564329,"median":-1.603098,"eighty":-1.220574,"marketCap":85891661},{"date":"2025-03-14","current":-2.672649,"twenty":-2.570137,"median":-1.649192,"eighty":-1.221023,"marketCap":125194918},{"date":"2025-03-21","current":-2.747078,"twenty":-2.60789,"median":-1.669929,"eighty":-1.222594,"marketCap":128681358},{"date":"2025-03-28","current":-2.594838,"twenty":-2.612537,"median":-1.719708,"eighty":-1.224155,"marketCap":121550002},{"date":"2025-04-04","current":-1.679468,"twenty":-2.612537,"median":-1.718575,"eighty":-1.22448,"marketCap":87161019},{"date":"2025-04-11","current":-1.557114,"twenty":-2.610061,"median":-1.684991,"eighty":-1.225254,"marketCap":80811079},{"date":"2025-04-17","current":-1.492618,"twenty":-2.608747,"median":-1.667384,"eighty":-1.226414,"marketCap":77463875},{"date":"2025-04-25","current":-1.557114,"twenty":-2.60789,"median":-1.641927,"eighty":-1.226584,"marketCap":80811079},{"date":"2025-05-02","current":-1.541757,"twenty":-2.60528,"median":-1.62119,"eighty":-1.227308,"marketCap":80014126},{"date":"2025-05-09","current":-1.710675,"twenty":-2.59278,"median":-1.624681,"eighty":-1.230226,"marketCap":88780614},{"date":"2025-05-13","current":-1.695319,"twenty":-2.588663,"median":-1.632359,"eighty":-1.235702,"marketCap":87983660}],"updateTime":1747218144944}}}